Holen Sie sich die Stockscreener-App
259.20
4.11%
-11.78
Schlusskurs vom Vortag:
$270.98
Offen:
$271
24-Stunden-Volumen:
427.58K
Relative Volume:
0.43
Marktkapitalisierung:
$6.46B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-28.27
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+45.07%
1M Leistung:
+54.46%
6M Leistung:
+483.78%
1J Leistung:
+290.38%
1-Tages-Spanne:
$256.50
$278.44
1-Wochen-Bereich:
$180.46
$278.44
52-Wochen-Spanne:
$26.70
$278.44
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
258.52 | 6.78B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
Needham Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - TradingView
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Nigeria
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com UK
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus
Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus
Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times
Truist Raises Price Target on Praxis Precision Medicines to $500 From $360, Keeps Buy Rating - marketscreener.com
HC Wainwright Reiterates 'Buy' Rating on PRAX with $340 PT | PRA - GuruFocus
Praxis (NASDAQ: PRAX) posts 53% seizure drop in EMBOLD trial, plans FDA NDA talks - Stock Titan
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data - Investing.com Australia
BTIG Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX: BTIG Raises Price Target to $507 with Buy Rating | PRAX St - GuruFocus
Praxis Precision Medicines (PRAX) Gaining Confidence on EMBOLD Study Optimism - Insider Monkey
Kennedy Capital Management LLC Increases Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week HighWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone - Yahoo Finance
Capital Fund Management S.A. Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicine (PRAX) Target Price Raised by HC Wainw - GuruFocus
Praxis Precision Medicines stock hits 52-week high at $241.0 By Investing.com - Investing.com Nigeria
Praxis Potential Breakthrough: Market Reactions - StocksToTrade
Another Praxis win provides much-needed progress in rare genetic epilepsies - BioCentury
PRAX Announces Breakthroughs in Neurological Treatments: Key Developments with FDA - StocksToTrade
Will Praxis Stock Climb Higher? - timothysykes.com
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle - BioWorld MedTech
Praxis Drug Trials Spark Optimism Amid Market Expansion - timothysykes.com
Praxis Precision Medicines Lights Up with Promising FDA Progress - timothysykes.com
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Yahoo Finance
Uptick in Praxis Precision Medicines: What’s Next? - StocksToTrade
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 (PRAX) - Seeking Alpha
Why PRAX Stock Climbs: Exploring Recent Successes - timothysykes.com
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Praxis Precision Medicine's Options: A Look at What the Big Money is Thinking - Benzinga
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):